Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
30 results
- D1.340 - Attack burden and patient-reported outcomes in adults with hereditary angioedema: associations with quality of life, pain, and coping strategies
- D1.336 - Barriers to Normalization with Existing Treatments Among People Living with Hereditary Angioedema in Europe
- D1.337 - Long-Term Safety, Tolerability, and Effectiveness of Berotralstat in Hereditary Angioedema: Interim Analysis of the APeX-N Post-Authorization Study
- D1.338 - Divergent Clinical and Functional Consequences of Canonical NF-κB Pathway Defects
- D1.339 - Renal and urinary tract disorders in inborn errors of immunity
- D1.341 - Severe Atopic Features with Prematurity and Ichthyosis: Ichthyosis Prematurity Syndrome
- D1.342 - Case Report: Off-Label Dosage of Berotralstat in Hereditary Angioedema
- D1.343 - Common Variable Immunodeficiency Associated Enteropathy: A Single-Center Experience
- D1.344 - Hidden Immunodeficiency in Adult Bronchiectasis: Lymphocyte Subsets, Humoral Defects, and Genetic Findings
- D1.346 - Clinically significant gastrointestinal endoscopic findings in asymptomatic patients with common variable immunodeficiency
- D1.347 - Lanadelumab in Children with Hereditary Angioedema Aged 2 to
D2.151 - HZ-Y030, an Oral STAT6 Degrader, Attenuates Type 2 Inflammation in Preclinical Asthma Models
D2.152 - Clinical and functional characteristics of patients with suspected epoxy resin-related occupational asthma
D2.155 - Mapping the Architecture and Spectrum of the Cough Hypersensitivity Questionnaire Across Respiratory Diseases
D2.158 - Circulating 1-methylnicotinamide can predict the treatment response of dupilumab in adult asthma
D2.149 - Occupational asthma in a tea-packaging worker: a case report
D2.150 - Clinical and functional outcomes after the diagnosis of baker’s asthma: ended vs. reduced exposure
D2.154 - Small airway dysfunction defined by reduced FEF25–75% identifies a distinct clinical phenotype in children with preserved FEV1
D2.156 - Defining the Systemic Boundary Between N-ERD and EGPA: Avoiding Misclassification of Eosinophilic Diseases
D2.157 - Clinical remission with tezepelumab in severe asthma: prevalence and predictors in a real-world multicentre study
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download